Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1996 Jul 1;184(1):121–130. doi: 10.1084/jem.184.1.121

Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes

PMCID: PMC2192679  PMID: 8691125

Abstract

Identification of cytolytic T lymphocyte (CTL) epitopes presented by major histocompatibility complex (MHC) class I molecules on tumor cells is critical for the design of active immunotherapy. We describe the use of combinatorial peptide libraries with defined amino acids in two MHC anchor positions to search for epitopes that are recognized by H-2Db- and Kb-restricted CTL specific for the mouse lymphoma EL4. An iterative strategy was used for screening libraries in which 16 amino acids were divided into 3 groups and 3 subgroups: alpha (AL, VT, FY); beta (GS, P, DE); gamma (KR, H, NQ). The proportions of each group and subgroup at individual peptide positions were changed in the library synthesis, and the effect of these changes on CTL activity was measured in a sensitive RMA-S cell assay. A single H-2Db epitope mimic was deduced from the original library that contained > 2 x 10(8) potential peptides and was at least 9 logs more potent than the original library. Immunization of syngeneic mice with this peptide elicited CTL that lysed EL4 cells as well as RMA-S cells pulsed with peptides isolated from Db molecules of EL4 cells, indicating functional similarity between the mimicking peptide and the naturally processed CTL epitope. Furthermore, adoptive transfer of such a CTL line had a therapeutic effect in mice with EL4 established as an ascites tumor. Two H-2Kb-restricted epitope mimics of the same tumor were also identified. Our method represents a novel approach for the construction of MHC class I-restricted targets that can serve as immunogens for active immunotherapy of cancer.

Full Text

The Full Text of this article is available as a PDF (881.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., Snoke K., Serra H. M., Kubo R. T., Sette A. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1994 Dec;1(9):751–761. doi: 10.1016/s1074-7613(94)80017-0. [DOI] [PubMed] [Google Scholar]
  2. Bellone M., Iezzi G., Manfredi A. A., Protti M. P., Dellabona P., Casorati G., Rugarli C. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells. Eur J Immunol. 1994 Nov;24(11):2691–2698. doi: 10.1002/eji.1830241118. [DOI] [PubMed] [Google Scholar]
  3. Blake J., Litzi-Davis L. Evaluation of peptide libraries: an iterative strategy to analyze the reactivity of peptide mixtures with antibodies. Bioconjug Chem. 1992 Nov-Dec;3(6):510–513. doi: 10.1021/bc00018a008. [DOI] [PubMed] [Google Scholar]
  4. Boon T., Cerottini J. C., Van den Eynde B., van der Bruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12:337–365. doi: 10.1146/annurev.iy.12.040194.002005. [DOI] [PubMed] [Google Scholar]
  5. Celis E., Tsai V., Crimi C., DeMars R., Wentworth P. A., Chesnut R. W., Grey H. M., Sette A., Serra H. M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2105–2109. doi: 10.1073/pnas.91.6.2105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen L., Ashe S., Brady W. A., Hellström I., Hellström K. E., Ledbetter J. A., McGowan P., Linsley P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992 Dec 24;71(7):1093–1102. doi: 10.1016/s0092-8674(05)80059-5. [DOI] [PubMed] [Google Scholar]
  7. Chen L., McGowan P., Ashe S., Johnston J., Li Y., Hellström I., Hellström K. E. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994 Feb 1;179(2):523–532. doi: 10.1084/jem.179.2.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chien Y. H., Davis M. M. How alpha beta T-cell receptors 'see' peptide/MHC complexes. Immunol Today. 1993 Dec;14(12):597–602. doi: 10.1016/0167-5699(93)90199-u. [DOI] [PubMed] [Google Scholar]
  9. Engelhard V. H. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol. 1994;12:181–207. doi: 10.1146/annurev.iy.12.040194.001145. [DOI] [PubMed] [Google Scholar]
  10. Feltkamp M. C., Smits H. L., Vierboom M. P., Minnaar R. P., de Jongh B. M., Drijfhout J. W., ter Schegget J., Melief C. J., Kast W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993 Sep;23(9):2242–2249. doi: 10.1002/eji.1830230929. [DOI] [PubMed] [Google Scholar]
  11. Gausepohl H., Boulin C., Kraft M., Frank R. W. Automated multiple peptide synthesis. Pept Res. 1992 Nov-Dec;5(6):315–320. [PubMed] [Google Scholar]
  12. Gavin M. A., Dere B., Grandea A. G., 3rd, Hogquist K. A., Bevan M. J. Major histocompatibility complex class I allele-specific peptide libraries: identification of peptides that mimic an H-Y T cell epitope. Eur J Immunol. 1994 Sep;24(9):2124–2133. doi: 10.1002/eji.1830240929. [DOI] [PubMed] [Google Scholar]
  13. Grohmann U., Bianchi R., Fioretti M. C., Fallarino F., Binaglia L., Uyttenhove C., Van Pel A., Boon T., Puccetti P. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide. Eur J Immunol. 1995 Oct;25(10):2797–2802. doi: 10.1002/eji.1830251013. [DOI] [PubMed] [Google Scholar]
  14. Heemels M. T., Ploegh H. Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem. 1995;64:463–491. doi: 10.1146/annurev.bi.64.070195.002335. [DOI] [PubMed] [Google Scholar]
  15. Houbiers J. G., Nijman H. W., van der Burg S. H., Drijfhout J. W., Kenemans P., van de Velde C. J., Brand A., Momburg F., Kast W. M., Melief C. J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol. 1993 Sep;23(9):2072–2077. doi: 10.1002/eji.1830230905. [DOI] [PubMed] [Google Scholar]
  16. Johnston J. V., Malacko A. R., Mizuno M. T., McGowan P., Hellström I., Hellström K. E., Marquardt H., Chen L. B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med. 1996 Mar 1;183(3):791–800. doi: 10.1084/jem.183.3.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kast W. M., Brandt R. M., Sidney J., Drijfhout J. W., Kubo R. T., Grey H. M., Melief C. J., Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol. 1994 Apr 15;152(8):3904–3912. [PubMed] [Google Scholar]
  18. Kast W. M., Roux L., Curren J., Blom H. J., Voordouw A. C., Meloen R. H., Kolakofsky D., Melief C. J. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2283–2287. doi: 10.1073/pnas.88.6.2283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lethé B., van den Eynde B., van Pel A., Corradin G., Boon T. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol. 1992 Sep;22(9):2283–2288. doi: 10.1002/eji.1830220916. [DOI] [PubMed] [Google Scholar]
  20. Li Y., Hellstrom K. E., Newby S. A., Chen L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med. 1996 Feb 1;183(2):639–644. doi: 10.1084/jem.183.2.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ljunggren H. G., Kärre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med. 1985 Dec 1;162(6):1745–1759. doi: 10.1084/jem.162.6.1745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mandelboim O., Vadai E., Fridkin M., Katz-Hillel A., Feldman M., Berke G., Eisenbach L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med. 1995 Nov;1(11):1179–1183. doi: 10.1038/nm1195-1179. [DOI] [PubMed] [Google Scholar]
  23. Marth J. D., Peet R., Krebs E. G., Perlmutter R. M. A lymphocyte-specific protein-tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA. Cell. 1985 Dec;43(2 Pt 1):393–404. doi: 10.1016/0092-8674(85)90169-2. [DOI] [PubMed] [Google Scholar]
  24. Peace D. J., Smith J. W., Chen W., You S. G., Cosand W. L., Blake J., Cheever M. A. Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med. 1994 Feb 1;179(2):473–479. doi: 10.1084/jem.179.2.473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rammensee H. G., Falk K., Rötzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol. 1993;11:213–244. doi: 10.1146/annurev.iy.11.040193.001241. [DOI] [PubMed] [Google Scholar]
  26. Rothbard J. B., Gefter M. L. Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol. 1991;9:527–565. doi: 10.1146/annurev.iy.09.040191.002523. [DOI] [PubMed] [Google Scholar]
  27. Ruppert J., Sidney J., Celis E., Kubo R. T., Grey H. M., Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 1993 Sep 10;74(5):929–937. doi: 10.1016/0092-8674(93)90472-3. [DOI] [PubMed] [Google Scholar]
  28. Sadovnikova E., Zhu X., Collins S. M., Zhou J., Vousden K., Crawford L., Beverley P., Stauss H. J. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papilloma virus E7 protein. Int Immunol. 1994 Feb;6(2):289–296. doi: 10.1093/intimm/6.2.289. [DOI] [PubMed] [Google Scholar]
  29. Schumacher T. N., Van Bleek G. M., Heemels M. T., Deres K., Li K. W., Imarai M., Vernie L. N., Nathenson S. G., Ploegh H. L. Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules. Eur J Immunol. 1992 Jun;22(6):1405–1412. doi: 10.1002/eji.1830220612. [DOI] [PubMed] [Google Scholar]
  30. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., Kast W. M., Melief C. J., Oseroff C., Yuan L., Ruppert J. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 1994 Dec 15;153(12):5586–5592. [PubMed] [Google Scholar]
  31. Slingluff C. L., Jr, Hunt D. F., Engelhard V. H. Direct analysis of tumor-associated peptide antigens. Curr Opin Immunol. 1994 Oct;6(5):733–740. doi: 10.1016/0952-7915(94)90077-9. [DOI] [PubMed] [Google Scholar]
  32. Townsend A., Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol. 1989;7:601–624. doi: 10.1146/annurev.iy.07.040189.003125. [DOI] [PubMed] [Google Scholar]
  33. Traversari C., van der Bruggen P., Luescher I. F., Lurquin C., Chomez P., Van Pel A., De Plaen E., Amar-Costesec A., Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992 Nov 1;176(5):1453–1457. doi: 10.1084/jem.176.5.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Udaka K., Wiesmüller K. H., Kienle S., Jung G., Walden P. Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries. J Exp Med. 1995 Jun 1;181(6):2097–2108. doi: 10.1084/jem.181.6.2097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Uenaka A., Ono T., Akisawa T., Wada H., Yasuda T., Nakayama E. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med. 1994 Nov 1;180(5):1599–1607. doi: 10.1084/jem.180.5.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Valmori D., Romero J. F., Men Y., Maryanski J. L., Romero P., Corradin G. Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. Eur J Immunol. 1994 Jun;24(6):1458–1462. doi: 10.1002/eji.1830240633. [DOI] [PubMed] [Google Scholar]
  37. Yang G., Hellström K. E., Mizuno M. T., Chen L. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. J Immunol. 1995 Oct 15;155(8):3897–3903. [PubMed] [Google Scholar]
  38. Yewdell J. W., Bennink J. R. Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol. 1992;52:1–123. doi: 10.1016/s0065-2776(08)60875-5. [DOI] [PubMed] [Google Scholar]
  39. Young J. W., Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med. 1996 Jan 1;183(1):7–11. doi: 10.1084/jem.183.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES